When Phyllis Burk was diagnosed with Crohn’s disease nearly 50 years ago, it wasn’t as simple as looking up information ...
Investor's Business Daily on MSN
AT&T Earnings Due. Verizon Dividend At Risk Under New CEO? 'Convergence' Battle Looms.
Third quarter earnings for AT&T are due Oct. 22. T-Mobile reports Q3 financial results Oct. 23 and Verizon on Oct. 29.
Foods that may hurt your gut health include ultra-processed and high-fat foods, red meat, artificial sweeteners, alcohol, and ...
Investor's Business Daily on MSN
Stock Market Today: Dow Hits Record But Gold Stocks Sink; Warren Buffett Stock Jumps (Live Coverage)
The Dow Jones Industrial Average and the other major stock indexes traded mixed in morning action Tuesday, as Wall Street ...
ORLANDO -- Utilization of a "total telemedicine pathway" for inflammatory bowel disease (IBD) surgery saved a considerable amount of mileage and time for patients treated at an academic IBD center, ...
AbbVie is going back to school to support patients with inflammatory bowel disease (IBD), enrolling “Abbott Elementary” star Tyler James Williams for a new campaign aimed at sparking deeper ...
Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets ...
Saudi Arabia – The 10th Future Inflammatory Bowel Disease (IBD) Gates Summit kicked off in Dubai, under the sponsorship of AbbVie Biopharmaceuticals, the global biopharmaceutical research and ...
Patients with inflammatory bowel disease (IBD) reported poorer health-related quality of life (HRQOL) than healthy individuals despite high remission rates, with alterations in gut microbiota more ...
India Today on MSN
Health Watch | Gut feeling: CSIR bets on microbes to heal chronic ills
What if your gut could hold the key to curing chronic disease? India’s premier science body, the Council of Scientific and ...
UK biotech OMass Therapeutics has revealed its first major pharma partnership, with Roche's Genentech unit paying $20 million upfront to tap into its expertise and find small-molecule therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results